国产格列齐特与进口达美康治疗NIDDM疗效比较

A Comparison of Efficacy between Gliclazide and Diamicron in the Treatment of Non-insulin-dependent Diabetes Mellitus

应用国产格列齐特治疗112例NIDDM患者,有效剂量为111.1±64.8mg/d(20～240mg/d)显著低于进口达美康。有效率为99.11％,显著高于进口达美康;格列齐特除具有降糖、降糖化血红蛋白,促进胰岛素分泌、提高血清基础胰岛素水平、降低血浆纤维蛋白原作用外,还具有调整脂类代谢紊乱的作用,其效果亦优于进口达美康。国产格列齐特生物利用度高、安全有效,是治疗NIDDM患者的一种理想口服降糖药。

Domestic gliclazide was used to treat 112 patients with non-insulin-dependent diabetes| mellitus (NIDDM),for the other 93 patients imported diamicron was used as controls. The daily oral dose of gliclazide ranged from 20-240(111. 1 + 64. 8)mg. After a 2 - 3 months course of treatment, mean fasting and 2-hour postprandial blood glucose, plasma fibrinogen, urinary glucose excretion and glycohemoglobin levels were reduced significantly (P<0. 01),glucose tolerance was elevated, serum insulin levels in fasting and each phase after glucose loading were increased appreciably (P< 0. 01), disorder of lipids metabolism was improved in gliclazide group. The efficacy dose of gli-clazide was lower than that of diamicron. Therapeutic efficacy and bioavailability were higher than those of diamicron. Side effects of gliclazide were minimal, similar to those of diamicron. The results of survey indicated that gliclazide was an effective and safe oral hypoglycemic agent for NID-DM.